Navigation Links
CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
Date:2/17/2012

WASHINGTON, Feb. 17, 2012 /PRNewswire/ -- The Consumer Healthcare Products Association (CHPA) today released the following statement regarding a new economic impact study that analyzed the potential economic consequences a prescription requirement for safe and effective cold and allergy medicines containing pseudoephedrine (PSE) would have on the state of Oklahoma. The study was conducted by the Economic Impact Group, LLC, and funded by a grant provided by the CHPA.

Some of the study's most compelling findings include the following impacts of a prescription requirement:  

  • An influx of more than 296,000 new doctor visits in Oklahoma, with costs reaching as much as $59 million in the state.
  • The productivity cost from missed days from work or school already accounts for an estimated $227 to $400 million from viral respiratory tract infections in Oklahoma.  These costs would climb considerably under a prescription requirement.

"The economic impact study in Oklahoma quantified what we already knew to be true: a prescription requirement for popular and reliable over-the-counter cold and allergy medicines will lead to higher healthcare costs for responsible consumers, lower productivity for Oklahoma businesses, and lost tax revenues for the state," said Scott Melville, president and CEO, CHPA. "Effectively reducing meth production in Oklahoma is a critically important goal, but it's important that methods employed to achieve that goal do not burden law-abiding Oklahomans with significant and unnecessary costs."

www.chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
2. Roche responds to announcement of IDEAL hepatitis C trial results
3. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
4. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
5. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
6. EPSScentral Responds to Pandemic Alert
7. Endologix Responds to Alleged Patent Infringement
8. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
9. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
10. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients
11. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... the nation's first interactive health literacy software tool, and the Cancer Patient Education ... of cancer patient education, today announce a new strategic alliance. , As ...
Breaking Medicine News(10 mins):